TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3360860
Drug: Teonova (theophylline)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teonova (theophylline) 600 mg administered 10 min before breakfast
Study: 3360860
Drug: Teonova (theophylline)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teonova (theophylline) 600 mg administered 60 min after breakfast
Study: 3360860
Drug: Teonova (theophylline)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teonova (theophylline) 600 mg administered 10 min before dinner
Study: 3360860
Drug: Teonova (theophylline)
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Teonova (theophylline) 600 mg administered 60 min after dinner
Study: 24512252
Drug: 17P (250mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17P (250mg weekly injections)
Study: 3307889
Drug: Grenz ray
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz ray therapy (3 Gy applied on six occasions at intervals of 1 week)
Study: 26080572
Drug: Qinghouyan lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinghouyan lozenge for 5 days
Study: 26080572
Drug: Qinghouyan oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinghouyan oral Liquid for 5 days
Study: 26080572
Drug: Qinghouyan lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinghouyan lozenge
Study: 26080572
Drug: Qinghouyan oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinghouyan oral Liquid
Study: 19553405
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (CJ) 240 mL once daily for 2 weeks
Study: 19553405
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage 240 mL once daily for 2 weeks
Study: 11133601
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.75 mg/kg preservative‐free S(+)‐ketamine and 0.75 mg/kg midazolam
Study: 11133601
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg preservative‐free S(+)‐ketamine
Study: 9695971
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus 5.0 microg/kg/d MGDF
Study: 9695971
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus MGDF
Study: 8205826
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial prophylaxis and sucralfate (1 g/6 hrs)
Study: 1097878
Drug: Salbutamol (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (3 X 2.0 mg)
Study: 1097878
Drug: Terbutalin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutalin (3 X 2.5 mg)
Study: 30582281
Drug: Low-dose prolonged-release
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prolonged-release tacrolimus
Study: 30582281
Drug: Standard-dose prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose prolonged-release tacrolimus
Study: 30582281
Drug: Low-dose prolonged-release
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prolonged-release tacrolimus + ACEi/ARB
Study: 30582281
Drug: Low-dose prolonged-release
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prolonged-release tacrolimus + OAHT
Study: 27906549
Drug: HFHC meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFHC meal with 30 g of insoluble dietary fiber
Study: 25913272
Drug: RTS,S/AS01 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 with booster dose (R3R group)
Study: 25913272
Drug: RTS,S/AS01 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 with comparator vaccine (R3C group)
Study: 25913272
Drug: Comparator vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator vaccine (C3C group)
Study: 21323490
Drug: Internet cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet cognitive behaviour therapy (CBT)
Study: 21323490
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behaviour therapy (CBT)
Study: 19776082
Drug: Electrocautery dissection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrocautery dissection and application of a collagen patch coated with human fibrinogen and thrombin (TachoSil)
Study: 19776082
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (ST) with stapling device
Study: 14742372
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream after ultrasound pretreatment
Study: 14742372
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream application for 5 min
Study: 14742372
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream application for 10 min
Study: 14742372
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream application for 15 min
Study: 14742372
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream application for 60 min without ultrasound pretreatment
Study: 9148253
Drug: Timolol hydrogel
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol hydrogel (T-Gel 0.1%)
Study: 26411031
Drug: CQR-300, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CQR-300, 300 mg daily
Study: 18829797
Drug: Higher rates
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher rates of infusion of intravenous fat emulsion
Study: 16060411
Drug: manidipine 20
Normalized name: manidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: manidipine 20 mg o.d. for 4 weeks
Study: 16060411
Drug: delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delapril 30 mg b.i.d. for 4 weeks
Study: 16060411
Drug: fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed combination of manidipine 10 mg plus delapril 30 mg o.d. for 8 weeks
Study: 12403690
Drug: Montelukast and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast and Budesonide (combination)
Study: 10879210
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment services
Study: 31126327
Drug: Siblings (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siblings (treatment with benznidazole)
Study: 18693600
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg per day)
Study: 15151516
Drug: Fexofenadine (FEX)
Normalized name: fexofenadine Oral Tablet [Wal-Fex]
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fexofenadine (FEX) 180 mg + Montelukast (ML) 10 mg
Study: 8228340
Drug: High-titer vaccine
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titer vaccine (100-fold greater than standard titer)
Study: 8228340
Drug: Medium-titer vaccine
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-titer vaccine (10-fold greater than standard titer)
Study: 3803483
Drug: Preparation interval
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation interval prior to verbal and spatial tasks
Study: 23682661
Drug: GSK2190915 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915 30 mg QD
Study: 20181971
Drug: Integrated antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated antiretroviral therapy during tuberculosis therapy (combined integrated-therapy groups)
Study: 20181971
Drug: Sequential antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential antiretroviral therapy after completion of tuberculosis therapy (sequential-therapy group)
Study: 17997391
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g)
Study: 11078178
Drug: Isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine 2.5 to 10 mg twice a day
Study: 11078178
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 to 20 mg twice a day
Study: 8712033
Drug: Neuroleptic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic medication (doses above 2000 mg chlorpromazine equivalents daily)
Study: 1281062
Drug: Subcutaneous salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous salmon calcitonin (100 U Calcitonin Sandoz) for 21 days plus physical treatment and early mobilization
Study: 28922338
Drug: Esmolol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.7 mg/kg bolus over 1 min followed by infusion at 10 μg/kg/min)
Study: 28922338
Drug: Remifentanil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.2 μg/kg/min infusion)
Study: 24942382
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg every 4 weeks (Q4W)
Study: 24013647
Drug: Combined CZP
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CZP arms (200 mg Q2W and 400 mg Q4W)
Study: 12468560
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 500 mg daily
Study: 8222743
Drug: Standard adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adhesive tape treatment
Study: 3518772
Drug: Fenclofenac at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenclofenac at 600 mg day-1
Study: 3518772
Drug: Fenclofenac at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenclofenac at 1200 mg day-1
Study: 3518772
Drug: Fenclofenac at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenclofenac at 1800 mg day-1
Study: 30286820
Drug: Policosanol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol (20 mg/day)
Study: 26626320
Drug: Rotigotine (optimal/maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine (optimal/maximum dose <16 mg/24h)
Study: 24185607
Drug: Patient-controlled levobupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled levobupivacaine 1.25 mg/ml via i.p. catheter as needed (maximum once per hour) with continuous saline infusion 10 ml/h
Study: 24185607
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine 1.25 mg/ml 10 ml/h and bolus saline as needed
Study: 24185607
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine
Study: 17725600
Drug: Lansoprazole (proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (proton pump inhibitor) for 4 weeks
Study: 12416946
Drug: Leflunomide added
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide added to existing methotrexate therapy
Study: 12416946
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to existing methotrexate therapy
Study: 10628925
Drug: Postal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postal administration with financial incentive
Study: 10628925
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration with financial incentive
Study: 10628925
Drug: Clinic visit
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic visit administration with financial incentive
Study: 10628925
Drug: Postal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postal administration without financial incentive
Study: 10628925
Drug: Telephone administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone administration without financial incentive
Study: 10628925
Drug: Clinic visit
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic visit administration without financial incentive
Study: 8845402
Drug: Intermittent oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent oral acyclovir (ACV)
Study: 1775083
Drug: Intranasal spray
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal spray (4 doses of an oil‐based P solution at a concentration of 2 mg/0.1 ml, total dose approximately 11 mg of P)
Study: 1775083
Drug: Ointment (quantity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment (quantity 0.1 ml, P concentration 20 mg/0.1 ml)
Study: 7068938
Drug: Diflunisal (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (all doses)
Study: 25524950
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered in the evening (2200 h)
Study: 25524950
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered in the morning (1000 h)
Study: 19300303
Drug: Stable isotope‐labelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable isotope‐labelled nicotine infusion
Study: 9341413
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution during the first 3 days of life in addition to being breastfed
Study: 8428871
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 5, 10, 15, and 20 mg
Study: 25790328
Drug: Resveratrol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (150 mg per day)
Study: 21936938
Drug: High-energy protein
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy protein supplement (HEPS)
Study: 15164887
Drug: Caffeine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (0.3 mg per kg per hour)
Study: 14673617
Drug: GaAs laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: GaAs laser treatment applied over three trigger points bilaterally and one point in the taut bands in trapezius muscle bilaterally with a frequency of 1000 Hz for 2 min over each point once a day for 10 days during a period of 2 weeks
Study: 14673617
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (laser instrument switched off) with the same treatment protocol
Study: 31048013
Drug: Cyclosporine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (4 mg/kg/d)
Study: 28507108
Drug: ABX464 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 (up to 150 mg once a day)
Study: 26644127
Drug: Constraint‐induced movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint‐induced movement therapy (CIMT) combined with motor and sensory‐motor interventions
Study: 26644127
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care occupational and physical therapy
Study: 21748303
Drug: After administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: After administration of a proton pump inhibitor
Study: 19922603
Drug: Postural exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postural exercise therapy
Study: 16508401
Drug: Ketamine (0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.24 mg/kg)
Study: 14987306
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily
Study: 14720267
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray 220 microg once daily
Study: 14720267
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (TAA) aqueous nasal spray
Study: 9313671
Drug: Spermatic-cord block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spermatic-cord block (10 mL of 0.5% plain bupivacaine)
Study: 9313671
Drug: Conventional analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesic regimen (general anaesthesia, fentanyl, and diclofenac)
Study: 8370132
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (10 mg) administered 60 minutes prior to GHRH (100 micrograms i.v. bolus)
Study: 8370132
Drug: Oral melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral melatonin (10 mg) administered 60 minutes prior to a submaximal dose (3 micrograms i.v. bolus) of GHRH
Study: 8370132
Drug: Oral pyridostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pyridostigmine (120 mg)
Study: 8370132
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of melatonin (10 mg) and pyridostigmine (120 mg)
Study: 3011310
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg nedocromil sodium
Study: 3011310
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg nedocromil sodium
Study: 3011310
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg nedocromil sodium
Study: 31951148
Drug: Limited controlling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited controlling method (L-K)
Study: 20304566
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between 25 Gy and lower doses (20 Gy and 15 Gy)
Study: 15647648
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (n=28)
Study: 15647648
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (n=30)
Study: 15647648
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (n=27)
Study: 12038875
Drug: Newer hypnotics
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer hypnotics
Study: 7666101
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg twice daily on days 2 and 3 and placebo on days 4 to 6
Study: 7666101
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg twice daily on days 2 to 6
Study: 9557622
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy for ALL
Study: 1131555
Drug: Behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviour therapy conducted by medical students
Study: 31846980
Drug: Active tACS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tACS (20 daily 40-min sessions, 77.5-Hz, 15-mA)
Study: 23743976
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 110 mg BID (DE 110)
Study: 23743976
Drug: Dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dabigatran etexilate 150 mg BID (DE 150)
Study: 19057983
Drug: ALA-PDT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT with 60 mg/kg and red laser light (1,000 J/cm)
Study: 19057983
Drug: ALA-PDT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT with 30 mg/kg
Study: 19057983
Drug: ALA-PDT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT with 60 mg/kg and red laser light
Study: 24718066
Drug: Kineflex-L Disc
Normalized name: Sus scrofa intervertebral disc preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kineflex-L Disc (investigational group)
Study: 17209164
Drug: Intradiscal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal and intraforaminal injections of a steroid, an anesthetic, and O(2)-O(3) mixture (group B)
Study: 17209164
Drug: Intradiscal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal and intraforaminal injections of a steroid and an anesthetic (group A)
Study: 10335537
Drug: Children with
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children with birthweight < 2500 g
Study: 7656629
Drug: Local radiotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local radiotherapy (7 Gy, three daily sessions, 10 to 15 days after thoracoscopy)
Study: 2789920
Drug: APD 30
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 30 mg single dose on day 1 (group A, n = 9)
Study: 2789920
Drug: APD 30
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 30 mg two consecutive doses on days 1 and 2 (group B, n = 9)
Study: 2789920
Drug: APD 60
Normalized name: APD-209
DrugBank: APD-209 (DB18759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APD 60 mg single dose on day 1 (group C, n = 9)